Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Chinese Patent Office
McKesson
UBS
Deloitte
Covington
Farmers Insurance
Medtronic
Cipla
Dow

Generated: February 18, 2018

DrugPatentWatch Database Preview

INVANZ Drug Profile

« Back to Dashboard

Which patents cover Invanz, and when can generic versions of Invanz launch?

Invanz is a drug marketed by Merck Sharp Dohme and is included in one NDA.

The generic ingredient in INVANZ is ertapenem sodium. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ertapenem sodium profile page.
Drug patent expirations by year for INVANZ
Pharmacology for INVANZ
Ingredient-typeCarbapenems
Drug ClassPenem Antibacterial

US Patents and Regulatory Information for INVANZ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, IV (INFUSION) 021337-001 Nov 21, 2001 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for INVANZ

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, IV (INFUSION) 021337-001 Nov 21, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, IV (INFUSION) 021337-001 Nov 21, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, IV (INFUSION) 021337-001 Nov 21, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme INVANZ ertapenem sodium INJECTABLE;INTRAMUSCULAR, IV (INFUSION) 021337-001 Nov 21, 2001 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for INVANZ
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Injection 1 g/vial ➤ Subscribe 6/20/2013

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Covington
Johnson and Johnson
Farmers Insurance
Merck
Queensland Health
AstraZeneca
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot